SCHEMBL10933335

SCHEMBL10933335

C#CCOc1ncccn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.61
POLB P06746 1/20 0.61
HSD17B10 Q99714 1/20 0.61
MAOB P27338 8/20 0.37
MAOA P21397 4/20 0.36
ACHE P22303 1/20 0.35
MAPT P10636 2/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
KMT2A Q03164 1/20 0.35
CA12 O43570 2/20 0.34
CA9 Q16790 2/20 0.34
GSTP1 P09211 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA4 P22748 1/20 0.34
CA7 P43166 1/20 0.34
NPC1 O15118 1/20 0.33
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5793591 0.78 MAPK1 (0.58) MAPK1POLBHSD17B10MAOBMAOA
SCHEMBL127630 0.76 MEN1 (0.37) MAPK1POLBHSD17B10ACHEMEN1
SCHEMBL690812 0.76 MAPK1 (1.00) MAPK1POLBHSD17B10MAOBMAOA
SCHEMBL9550693 0.74 POLB (0.48) MAPK1POLBHSD17B10MAOBMAOA
SCHEMBL6934276 0.71 GRM5 (0.36) MAPK1POLBHSD17B10MEN1KMT2A
SCHEMBL10339328 0.71 NR1I2 (0.42) MAPK1POLBHSD17B10
SCHEMBL21936377 0.70 POLB (0.38) MAPK1POLBHSD17B10MAOBMAOA
SCHEMBL30453732 0.69 MAOB (0.44) MAPK1POLBHSD17B10MAOBMAOA
SCHEMBL7394763 0.69 S1PR4 (0.46) MAPK1POLBHSD17B10MAOBMAOA
SCHEMBL3645477 0.69 CHRNB2 (0.45) MAPK1POLBHSD17B10MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-60193971-A None JP disclosed
US-20260109677-A1 COMPOUNDS, DEVICES, AND USES THEREOF SIGILON THERAPEUTICS INC (US) 2026-04-23 US disclosed
US-12522571-B2 Compounds, devices, and uses thereof SIGILON THERAPEUTICS, INC. (US) 2026-01-13 US disclosed
US-20240279187-A1 COMPOUNDS, DEVICES, AND USES THEREOF SIGILON THERAPEUTICS, INC. 2024-08-22 US disclosed
US-11945786-B2 Compounds, devices, and uses thereof SIGILON THERAPEUTICS, INC. (US) 2024-04-02 US disclosed
US-20200039943-A1 COMPOUNDS, DEVICES, AND USES THEREOF SIGILON THERAPEUTICS, INC. 2020-02-06 US disclosed
US-20200039943-A1 COMPOUNDS, DEVICES, AND USES THEREOF SIGILON THERAPEUTICS, INC. 2020-02-06 US disclosed
WO-2018067615-A1 COMPOUNDS, DEVICES, AND USES THEREOF SIGILON THERAPEUTICS, INC. (US) 2018-04-12 WO disclosed
JP-S60193971-A IODOPROPARGYLOXYPYRIMIDINE DERIVATIVE, ITS PREPARATION AND FUNGICIDE FOR AGRICULTURAL AND HORTICULTURAL PURPOSES MITSUI TOATSU CHEM INC 1985-10-02 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200039943-A1 COMPOUNDS, DEVICES, AND USES THEREOF SLC10A1, SLCO1B3, SLC5A1 MAPK1 1557/4885POLB 3072/4885HSD17B10 793/4885
US-11945786-B2 Compounds, devices, and uses thereof SLC10A1, SLCO1B3, SLC5A1 MAPK1 1557/4885POLB 3072/4885HSD17B10 793/4885
US-20240279187-A1 COMPOUNDS, DEVICES, AND USES THEREOF SLC10A1, SLCO1B3, SLC5A1 MAPK1 1557/4885POLB 3072/4885HSD17B10 793/4885
US-20260109677-A1 COMPOUNDS, DEVICES, AND USES THEREOF NR3C2, AGTR1, CHRM1 MAPK1 1311/4885POLB 3178/4885HSD17B10 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.